Management Team

A. J. Kazimi, is Chief Executive Officer and Chairman of the Board of Directors at CET. Previously, Mr. Kazimi helped guide and build the international biopharmaceutical company Therapeutic Antibodies Inc. As President and Chief Operating Officer, he made key contributions to the company’s growth through its IPO and initial product launches, including oversight of operations in three countries, closing more than $30 million in product agreements, and steering the company through debt and equity financings totaling more than $100 million. At Brown-Forman Corporation, Mr. Kazimi held a series of management positions and was involved in launching several new products. Mr. Kazimi serves on the board of directors for the Nashville Health Care Council, an industry association representing the largest concentration of healthcare companies in the U.S., and previously served on the board of directors for Aegis Toxicology Sciences Corporation, a federally certified forensic toxicology laboratory. Mr. Kazimi’s MBA is from the Owen Graduate School of Management at Vanderbilt University.

 

Diane S. Keeney, Ph.D., is Program Specialist at CET and manages the development activities and project teams for the early-stage technologies in CET’s project portfolio. Formerly appointed Assistant Professor of Medicine at Vanderbilt University (now Adjunct Assistant Professor), Dr. Keeney was Principal Investigator of federally-funded research programs at Vanderbilt and the Department of Veterans Affairs in Nashville. Dr. Keeney brings to the CET development team technical expertise in discovery research, nonclinical study design, writing proposals and winning competitive grant awards. Dr. Keeney’s original research is published in peer-reviewed biomedical journals.

 

Leo Pavliv, MBA, R.Ph.,RAC, is Executive Vice President of Operations and Chief Development Officer at Cumberland Pharmaceuticals Inc. Mr. Pavliv oversees development activities for Cumberland Pharmaceuticals’ marketed and pipeline drug products and the early-stage drug candidates in CET’s project portfolio. A seasoned biotechnology and pharmaceutical executive, Mr. Pavliv has more than 25 years of experience developing pharmaceutical and biological products at Parke-Davis, National Patent Development Corporation, Agouron, ProCyte, Cato, and now Cumberland. Mr. Pavliv has managed the product development process from concept through pre-formulation, formulation and scale-up stages through commercial manufacturing and commercialization. A wide breadth of pharmaceutical development experience covers diverse product types and dosage forms. In addition to four issued patents, Mr. Pavliv has authored and reviewed regulatory submissions to the FDA and foreign regulatory agencies, articles and book chapters and presentations delivered at industry meetings on topics relating to chemistry, manufacturing and controls.

 

Joshua Trantum - Cumberland Pharmaceuticals Joshua Trantum, Ph.D., is CET’s Development Director. Dr. Trantum oversees sourcing, evaluating, and negotiating new biopharmaceutical product and technology opportunities. He is also involved with supporting the resulting product development, project management activities, and funding initiatives. Before joining Cumberland, Dr. Trantum led a team of researchers supported by a $5 million global health diagnostics grant funded by the Gates Foundation. He managed the associated intellectual property in coordination with the technology transfer center and delivered favorable proof concept results for a multiplexed point of care instrument. He started his biomedical career as Senior Engineer at Contour Medical Technology where he helped lead the invention, successful development and FDA approval of a radio-translucent defibrillation medical device which went on to capture a dominant share of the relevant market. Prior to joining CET, Dr. Trantum served as President of Immunonet Biosciences, LLC, a developer of companion diagnostics for antibody therapeutics, which he co-founded and led to a clinical stage of development.

 

Joseph O. Rolwing, MBA, is Director of the CET Life Sciences Center, having retired in 2010 from the concurrent position President and Executive Director of the Tennessee Biotechnology Association (now known as Life Science Tennessee). Mr. Rolwing’s 38 years of experience in the healthcare industry includes former positions as Vice President and Business Manager for Genetics Associates, Inc., a $3.2 million diagnostic medical lab, and Vice President of Corporate Affairs for Centerstone Community Mental Health Centers, Inc., where he managed care contracts, budgeting, risk management, billing and accounts receivable. Mr. Rolwing also served as Special Projects Director and Finance Director for the Helen Ross McNabb Center in Knoxville, Tennessee. His MBA is from the University of North Carolina-Chapel Hill.

 

Andrew Vila, Ph.D., is Formulation Scientist at Cumberland Pharmaceuticals Inc. and manages Cumberland’s formulation laboratories. Dr. Vila provides formulation and analytical support for Cumberland Pharmaceuticals’ marketed and pipeline drug products and early-stage drug candidates in CET’s project portfolio. Previously, Dr. Vila was appointed Post-doctoral Fellow and then Research Instructor for the Vanderbilt Institute of Chemical Biology. Dr. Vila’s original research is published in peer-reviewed biochemical journals.